Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study

External validation of the ITA.LI.CA prognostic system for patients with hepatocellular carcinoma: A multicenter cohort study

(2018) Mauro Borzio et al.   HEPATOLOGY

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

(2015) Andrew X Zhu et al.   LANCET ONCOLOGY

Advances in targeted therapies for hepatocellular carcinoma in the genomic era

(2015) Josep M. Llovet et al.   Nature Reviews Clinical Oncology

Prognostic Value of Serum AFP, AFP-L3, and GP73 in Monitoring Short-term Treatment Response and Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation

(2014) Nan-Ya Wang et al.   Asian Pacific Journal of Cancer Prevention

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

(2014) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer

(2013) A. X. Zhu et al.   CLINICAL CANCER RESEARCH

The Critical Role of Vascular Endothelial Growth Factor in Tumor Angiogenesis

(2012) A. Amini et al.   CURRENT CANCER DRUG TARGETS

Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: A subgroup analysis

(2012) Khairuddin Memon et al.   JOURNAL OF HEPATOLOGY

Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma

(2012) Nicola Personeni et al.   JOURNAL OF HEPATOLOGY

Vascular endothelial growth factors and receptors: Anti-angiogenic therapy in the treatment of cancer

(2011) Sònia Tugues et al.   MOLECULAR ASPECTS OF MEDICINE

HCC and angiogenesis: possible targets and future directions

(2011) Andrew X. Zhu et al.   Nature Reviews Clinical Oncology

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2010) S. Jelic et al.   ANNALS OF ONCOLOGY

Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2

(2010) Jennifer L. Spratlin et al.   JOURNAL OF CLINICAL ONCOLOGY

Early α-fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma

(2010) Beom Kyung Kim et al.   LIVER INTERNATIONAL

Alpha-Fetoprotein Response After Locoregional Therapy for Hepatocellular Carcinoma: Oncologic Marker of Radiologic Response, Progression, and Survival

(2009) Ahsun Riaz et al.   JOURNAL OF CLINICAL ONCOLOGY

Serum  -Fetoprotein Response as a Surrogate for Clinical Outcome in Patients Receiving Systemic Therapy for Advanced Hepatocellular Carcinoma

(2009) S. R. Vora et al.   ONCOLOGIST

Diagnosis of hepatocellular carcinoma

(2009) Asmaa I Gomaa et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Prognostic factors after liver resection for hepatocellular carcinoma with hepatitis B virus-related cirrhosis: The surgeon's role in survival

(2008) X.-F. Zhang et al.   EJSO

New Utility of an Old Marker: Serial α-Fetoprotein Measurement in Predicting Radiologic Response and Survival of Patients With Hepatocellular Carcinoma Undergoing Systemic Chemotherapy

(2008) Stephen L. Chan et al.   JOURNAL OF CLINICAL ONCOLOGY